- Home
- MNPR vs AUTL Comparison
MNPR vs AUTL Comparison
Compare MNPR & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MNPR | AUTL |
|---|---|---|
| Founded | 2014 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | 752 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 368.9M | 407.2M |
| IPO Year | 2019 | 2025 |
Fundamental Metrics
Financial Performance| Metric | MNPR | AUTL |
|---|---|---|
| Price | $53.06 | $1.44 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 4 |
| Target Price | ★ $107.00 | $8.50 |
| AVG Volume (30 Days) | 168.5K | ★ 1.7M |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 54.99 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $10,120,000.00 |
| Revenue This Year | N/A | $80.32 |
| Revenue Next Year | N/A | $53.96 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 496.00 |
| 52 Week Low | $28.40 | $1.15 |
| 52 Week High | $105.00 | $2.70 |
Technical Indicators
Market Signals| Indicator | MNPR | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 39.70 | 46.04 |
| Support Level | $50.77 | $1.22 |
| Resistance Level | $60.67 | $1.52 |
| Average True Range (ATR) | 3.03 | 0.08 |
| MACD | -0.32 | 0.01 |
| Stochastic Oscillator | 25.60 | 28.99 |
Price Performance
Historical ComparisonAbout MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.